OPKO Health (OPK) director receives 30,000-share stock option award at $1.42

Rhea-AI Filing Summary

OPKO Health director Prem A. Lachman received a new stock option grant. On June 18, 2026, he was awarded options for 30,000 shares of OPKO Health common stock at an exercise price of $1.42 per share. These options are compensation-related, not an open-market purchase, and bring his directly held option position reported in this filing to 30,000 derivative shares.

Insights

Equity compensation analyst

Director received a routine option grant, with no open-market buying or selling.

Director Prem A. Lachman was granted stock options for 30,000 shares of OPKO Health common stock at an exercise price of $1.42 per share. The grant is coded as an A transaction, meaning a compensation-related award rather than a market trade.

The options are exercisable into 30,000 common shares and expire on June 17, 2036. Because there are no open-market purchases or sales and this is a standard equity award, the informational value for investors is limited and does not, by itself, signal a change in Lachman’s view of the stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lachman Prem A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	30,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 30,000 shares (Direct)

Key Figures

Option grant size: 30,000 shares Exercise price: $1.42 per share Post-grant derivative holdings: 30,000 derivative shares +2 more

5 metrics

Option grant size 30,000 shares Stock options granted on June 18, 2026

Exercise price $1.42 per share Conversion or exercise price of stock options

Post-grant derivative holdings 30,000 derivative shares Total options following transaction

Expiration date June 17, 2036 Stock option expiration

Transaction code A (grant, award, or other acquisition) Form 4 transaction classification

Key Terms

Stock Option (Right to Buy), conversion_or_exercise_price, Grant, award, or other acquisition, derivativeTransactionCount

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

conversion_or_exercise_price financial

"conversion_or_exercise_price: 1.4200"

Grant, award, or other acquisition regulatory

"transaction_code_description: Grant, award, or other acquisition"

derivativeTransactionCount regulatory

"derivativeTransactionCount: 1"

FAQ

What did OPKO Health (OPK) director Prem A. Lachman report on this Form 4?

He reported receiving a stock option grant for 30,000 shares of OPKO Health common stock. The options were awarded as compensation, not bought in the market, and give him the right to purchase shares at a fixed exercise price of $1.42.

Is Prem A. Lachman buying or selling OPKO Health (OPK) stock in this filing?

He is not buying or selling shares in the open market. The Form 4 shows a grant of stock options coded as an award, giving him rights to acquire 30,000 shares at $1.42, which is typical equity compensation for a director role.

How many OPKO Health (OPK) options did Prem A. Lachman receive and at what price?

He received stock options covering 30,000 underlying shares of OPKO Health common stock. The stated exercise price is $1.42 per share, meaning he can purchase those shares at $1.42 if he chooses to exercise the options during their term.

When do Prem A. Lachman’s OPKO Health (OPK) options expire?

The options reported in this filing are scheduled to expire on June 17, 2036. Until that expiration date, subject to any vesting conditions, Lachman has the right to exercise the options to acquire OPKO Health common shares at the fixed $1.42 exercise price.

Does this OPKO Health (OPK) Form 4 indicate any remaining derivative positions for Prem A. Lachman?

The filing shows 30,000 derivative shares following the transaction, corresponding to the newly granted stock options. The derivative summary section does not list additional option or warrant positions beyond this grant, so only this 30,000-share option award is visible here.

What does the transaction code “A” mean in Prem A. Lachman’s OPKO Health (OPK) Form 4?

Code “A” on Form 4 signifies a grant, award, or other acquisition of a security, typically as compensation. In this case, it reflects OPKO Health granting Lachman stock options, rather than him purchasing shares or options in an open-market transaction with cash.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 05:38 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lachman Prem A

(Last) (First) (Middle)

OPKO HEALTH, INC.

4400 BISCAYNE BLVD.

(Street)

MIAMI FLORIDA 33137

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OPKO HEALTH, INC. [ OPK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.42	06/18/2026		A		30,000		06/18/2027	06/17/2036	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

	Steven D. Rubin, Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)